Neurocrine Biosciences, Inc. (NBIX) Q3 2019 Earnings Results

Neurocrine Biosciences Misses on EPS, Stock Down 1.2%

Neurocrine Biosciences reported a lower-than-expected EPS, which contributed to a 1.2% decline in stock price. The lack of revenue data and guidance updates may raise concerns among investors. Management's defensive tone suggests they are navigating challenges but remain focused on future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.56	N/A	-19.90%

Management

Management commentary

Tone: Defensive

Overall, management conveyed a cautious outlook, highlighting ongoing challenges. They reiterated their commitment to long-term strategies.

Management acknowledged the challenges faced this quarter.

They emphasized a focus on long-term growth despite current setbacks.

Neurocrine Biosciences Misses on EPS, Stock Down 1.2%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS, Stock Down 1.2%

Key numbers

Management commentary